Aptorum Group Limited Class A Ordinary Shares (APM) is a publicly traded Healthcare sector company. As of July 8, 2026, APM trades at $0.78 with a market cap of $6.53M and a P/E ratio of 0.00. APM moved +0.00% today. Year to date, APM is -30.59%; over the trailing twelve months it is -14.02%. Its 52-week range spans $0.46 to $7.49. Rallies surfaces APM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aptorum and DiamiR Reveal 3 Biomarker Studies at AAIC; Merger Closing Pre-Fiscal 2027: Aptorum Group and DiamiR Biosciences will present three biomarker studies at the 2026 Alzheimer’s Association International Conference July 11–15, covering plasma-based APOE genotyping and microRNA markers of Alzheimer’s progression. The all-stock merger approved June 9 is due to close before fiscal 2027, renaming the combined company Niki BioSolutions.
| Metric | Value |
|---|---|
| Price | $0.78 |
| Market Cap | $6.53M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.49 |
| 52-Week Low | $0.46 |
| Volume | 3.28K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
APM analyst coverage data. Average price target: $0.00.